Latest News

Ohr Pharmaceuticals Surges 82% On Merger Agreement With NeuBase Therapeutics Inc.

Ohr Pharmaceuticals Surges 82% On Merger Agreement With NeuBase Therapeutics Inc.

Ohr Pharmaceuticals (OHRP) soared more than 82% in pre-market trade on Thursday after the company said it has agreed to merge with NeuBase Therapeutics Inc. Stockholders of NeuBase would become the majority holders of the combined company. The proposed merger will create a public company focused on advancing NeuBase’s peptide-nucleic acid antisense oligonucleotide, or PATrOL, technology platform to develop therapies […]

Apple’s Price Target From BMO Slashed to $153 From $213, Rating Kept at Market Perform

Apple’s Price Target From BMO Slashed to $153 From $213, Rating Kept at Market Perform

Apple (AAPL) received a sharp cut to its price target from BMO Capital Markets late Wednesday after the consumer-technology company reduced its fiscal Q1 revenue guidance, citing greater-than-expected economic weakness in some emerging markets and fewer iPhone upgrades than it anticipated. BMO’s new price target on the stock is $153 per share, down from $213. The shares closed Wednesday’s session […]

Athenex Joins With Chinese Partner on Skin-Cancer Drug; to Receive $14.5 Million

Athenex (ATNX) said Thursday it has entered into a licensing and partnership agreement with Chongqing Jingdong Junzhuo Pharmaceutical to develop and commercialize its drug KX2-391 for the treatment of actinic keratosis and oncology indications in China. Athenex said it will receive an upfront payment of $14.5 million, possible milestone payments of up to $15 million, and initial royalty payments of […]

US Stock Futures Sink After Apple’s Q1 Revenue Warning

US stock futures dropped sharply on Thursday after Apple (AAPL) slashed its fiscal Q1 revenue outlook, blaming a slowing Chinese economy. Oil prices nudged higher, buoyed by a reported drop in December crude exports from Saudi Arabia, with global benchmark Brent crude up 0.97%, and US crude West Texas Intermediate up 0.21% recently. At 8:15 am ET, the national employment […]

Sesen Bio Posts ‘Clinically Meaningful’ Data In Phase 3 Vicinium Trial; Shares Rise Nearly 3%

Sesen Bio Inc. (SESN) shares rose 2.7% during Thursday’s pre-market session after the biotech firm posted positive preliminary efficacy data from its ongoing phase 3 trial of Vicinium to treat patients with high-grade non-muscle invasive bladder cancer. Data from the Vista trial showed “clinically meaningful” complete response rates and the treatment was shown to be generally well-tolerated, the company said. […]